• Further to the agreement signed with NSPA (NATO Support and Procurement Agency), IBATECH Tecnología has supplied a BSL-3 mobile laboratory designed specifically for the detection of anthrax. The project will test samples of land potentially contaminated with anthrax, with the aim to strengthen the customer nation’s CBRN capabilities and mitigate risk posed by hazardous biological agents.
    The BSL-3 lab has been built to fit into a 20ft ISO container in order to enable effective transportation and deployment. The lab has been fitted with a stand-alone energy unit and, jacks for loading/ offloading, a HEPA filter and pressure system, climate control, and decontamination equipment.

  • Announced on October 2nd, the US Department of Health and Human Services (HHS) has allocated the first funding under Project BioShield for Ebola countermeasures.
    This funding will add add two vaccines and two treatments to the Strategic National Stockpile (SNS): a single-dose vaccine licensed by Merck, a prime-boost vaccine regimen from Johnson & Johnson, and monoclonal antibody treatments from Mapp Biopharmaceutical and Regeneron Pharmaceuticals.
    The $170.2 million in Project BioShield funds covers late-stage development and buys up to 1.13 million vaccine regimens and an unspecified number of treatment courses of the two drugs.

  • Marine Fighter Attack Squadron 251, also known as the “Thunderbolts”, stationed at Marine Corps Air Station Beaufort, South Carolina, continue to showcase unit readiness through training for every possible scenario, while forward deployed to MCAS Iwakuni, Japan.

    The Thunderbolts have intensified training on familiarizing aircrew members with the Joint Protective Aircrew Ensemble (JPACE) and respirator, a pilot’s Chemical Biological Radiological Nuclear Defense equipment, while still maintaining focus on the squadron’s mission.

  • Follow us on Twitter
  • Subscribe to CBRNe news